apixaban

Antithrombotics

Effects Antithrombotic Anticoagulant Fibrinolytic Active ingredients Salicylates: Acetylsalicylic acid 100 mg (Aspirin Cardio). P2Y12 antagonists: Clopidogrel (Plavix, generics). Prasugrel (Efient) Ticagrelor (Brilique) GP IIb/IIIa antagonists: Abciximab (ReoPro) Eptifibatide (Integrilin) Tirofiban (Aggrastat) PAR-1 antagonists: Vorapaxar (Zontivity) Vitamin K antagonists (coumarins): Phenprocoumon (Marcoumar). Acenocoumarol (Sintrom) Not on sale in many countries: dicoumarol, warfarin. Heparins: Heparin sodium Heparin-Calcium … Antithrombotics

Andexanet Alfa

Products Andexanet alfa was approved in the United States in 2018, in the EU in 2019, and in many countries in 2020 as a powder for the preparation of an infusion solution (Ondexxya). Structure and properties Andexanet alfa is a recombinant, modified, and enzymatically inactive factor Xa. The drug is produced by biotechnological methods. Effects … Andexanet Alfa

Apixaban: Effects, Uses & Risks

Apixaban is a relatively new drug prescribed to prevent thrombosis. It is used in patients who have undergone knee replacement surgery or hip replacement surgery. In this case, it is one of the preferred preparations because it can be administered in tablet form and is easier to dose than other preparations that also prevent blood … Apixaban: Effects, Uses & Risks

Apixaban

Products Apixaban has been approved in many countries since 2011 in the form of film-coated tablets (Eliquis). Structure and properties Apixaban (C25H25N5O4, Mr = 460.0 g/mol) was developed starting from razaxaban. It is an oxopiperidine and pyrazole derivative. Effects Apixaban (ATC B01AF02) has antithrombotic properties. It is an oral, direct, potent, selective, and reversible inhibitor … Apixaban

DOAK

Products Direct oral anticoagulants (abbreviation: DOAKs) are commercially available in the form of film-coated tablets and capsules. By definition, they are oral drugs. Some representatives of the corresponding drug groups are also available as infusion preparations. Rivaroxaban (Xarelto) and dabigatran (Pradaxa) were the first active ingredients to be approved in 2008. The DOAKs were developed … DOAK

Dabigatran

Products Dabigatran is commercially available in capsule form (Pradaxa). It has been approved in many countries since 2012. It was first approved in 2008. Structure and properties Dabigatran (C25H25N7O3, Mr = 471.5 g/mol) is present in drugs as mesilate and in the form of the prodrug dabigatran etexilate, which is metabolized in the organism by … Dabigatran

Deep Vein Thrombosis

Symptoms The possible symptoms and signs of deep vein thrombosis include: Pain or cramping in the legs Swelling (edema), feeling of tension Warmth sensation, overheating Reddish to blue-purple discoloration of the skin Increased visibility of the superficial veins The symptoms are rather nonspecific. Deep vein thrombosis may also be asymptomatic and discovered by chance. A … Deep Vein Thrombosis

Factor Xa Inhibitors

Products Direct factor Xa inhibitors are commercially available in the form of film-coated tablets and capsules. In 2008, rivaroxaban (Xarelto) was the first agent in this group to be approved in many countries and in the EU. Today, there are other drugs on the market, which are listed below. Like thrombin inhibitors, these active ingredients … Factor Xa Inhibitors

Alternatives to Marcumar®

Synonyms in a broader sense Phenprocoumon (active ingredient name), coumarins, vitamin K antagonists (inhibitors), anticoagulants, anticoagulants What are alternatives to Marcumar®? The commercial product Pradaxa® contains the active ingredient dabigatran etexilate. The active ingredient is a direct thrombin inhibitor. This means that it directly and reversibly inhibits so-called thrombin. Thrombin plays an important role in … Alternatives to Marcumar®

Xarelto® | Alternatives to Marcumar®

Xarelto® The commercial product Xarelto® contains the active ingredient rivaroxaban. It is a direct and reversible inhibitor of coagulation factor 10, which also plays a very important role in blood coagulation. The indications are similar to those for other blood-clotting inhibitors. Rivaroxaban has a half-life of 7-11 hours. This makes it more flexibly controllable. Under … Xarelto® | Alternatives to Marcumar®